The antioxidant (→)-epigallocatechin-3-gallate inhibits activated hepatic stellate cell growth and suppresses acetaldehyde-induced gene expression

Anping CHEN*†, Li ZHANG‡, Jianye XU* and Jun TANG†‡

*Department of Pathology, Louisiana State University Health Sciences Center in Shreveport, Shreveport, LA 71130, U.S.A., †Department of Cell Biology and Anatomy, Louisiana State University Health Sciences Center in Shreveport, Shreveport, LA 71130, U.S.A., and ‡Section of Gastroenterology, Department of Medicine, The University of Chicago, Chicago, IL 60637, U.S.A.

Activated hepatic stellate cells (HSC) are the primary source of excessive production of extracellular matrix during liver fibrogenesis. Although the underlying mechanisms remain incompletely understood, it is widely accepted that oxidative stress plays a critical role in liver fibrogenesis. Suppression of HSC growth and activation, as well as induction of apoptosis, have been proposed as therapeutic strategies for treatment and prevention of this disease. In the present report, we elucidated, for the first time, effects of the antioxidant (→)-epigallocatechin-3-gallate (EGCG), a major (and the most active) component of green tea extracts, on cultured HSC growth and activation. Our results revealed that EGCG significantly inhibited cultured HSC growth by inducing cell cycle arrest and apoptosis in a dose- and time-dependent manner. In addition, EGCG markedly suppressed the activation of cultured HSC as demonstrated by blocking transforming growth factor-β signal transduction and by inhibiting the expression of α1(I) collagen, fibronectin and α-smooth muscle actin genes induced by acetaldehyde, the most active metabolite of ethanol. Furthermore, EGCG reacted differently in the inhibition of nuclear factor-κB activity between cultured HSC with or without acetaldehyde stimulation. Taken together, our results indicated that EGCG was a novel and effective inhibitor for activated HSC growth and activation in vitro. Further studies are necessary to evaluate the effect of this polyphenol in prevention of quiescent HSC activation in vivo, and to further elucidate the underlying mechanisms.

Key words: alcohol, apoptosis, fibrogenesis, gene regulation, green tea extract.

INTRODUCTION

Hepatic fibrosis occurs as a wound-healing process after many forms of chronic liver injury, including virus infection, autoimmune liver diseases and sustained alcohol abuse [1]. Hepatic fibrogenesis is a process where production of extracellular matrix (ECM) surpasses degradation. Without effective treatments, reversible hepatic fibrosis at an early stage leads to irreversible cirrhosis. Suppression of hepatic fibrogenesis and prevention of cirrhosis has attracted the attention of researchers from the therapeutic perspective. Hepatic stellate cells (HSC), previously termed fat- or vitamin A-storing cells, or Ito cells, are the most relevant cell type for over-production of ECM and for the development of liver fibrosis. Upon stimulation, quiescent HSC become activated and trans-differentiate into myofibroblast-like cells characterized by several key phenotypic changes, including an increase in proliferation, accumulation of ECM, including α1(I) collagen, expression of α-smooth muscle actin (α-SMA) and loss of stored vitamin A droplets, as recently reviewed by Friedman [2]. Culturing quiescent HSC on plastic plates causes spontaneous activation leading to a myofibroblast-like phenotype, mimicking the process seen in vitro. This provides a simple and useful model for studying activation of these cells. Induction of apoptosis has recently been proposed as a strategy for terminating proliferation of activated HSC during liver fibrogenesis [3,4].

Although the underlying mechanisms remain incompletely understood, accumulating evidence has indicated that oxidative stress plays critical roles in activation of HSC [2,5,6]. Reducing oxidative stress by antioxidants, such as α-tocopherol (vitamin E) and butylated hydroxytoluene, blocked HSC activation and suppressed the expression of collagen genes in HSC in vitro [5], as well as preventing fibrosis in iron-overloaded rat liver in vivo [7]. Experimental results suggested that reducing oxidative stress by antioxidants could be a potential and effective therapeutic strategy for treatment and prevention of hepatic fibrogenesis. However, the therapeutic efficacy of currently well-known antioxidants, such as superoxide dismutase, vitamin E and ascorbic acid, in treatment of human hepatic fibrosis is generally unimpressive [8].

Natural antioxidants, such as polyphenols from green tea extracts, have recently attracted considerable attention for preventing oxidative stress-related diseases including cancers, cardiovascular diseases and degenerative diseases [9]. Green tea is the most consumed beverage in the world [10]. (→)-Epigallocatechin-3-gallate (EGCG) is a major constituent and the most potent antioxidant of the polyphenols purified from green tea (Figure 1) [11]. The antioxidant potential of EGCG is far greater than that of vitamin E and/or C [12], which might allow it to succeed where other antioxidants have failed in preventing oxidative stress-related diseases. This polyphenol was previously shown not to harm the liver or kidney in vivo [13]. Its potent antioxidant capability and long history as beverage without adverse health effects make it a possible alternative to vitamin E for therapeutic treatment. Effects of the antioxidant EGCG on HSC growth and activation, however, have not been studied. The basis of this communication is to evaluate effects of this natural phyto-antioxidant on cultured HSC growth and acti-

---

**Abbreviations used:** BrdU, bromodeoxyuridine; DMEM, Dulbecco’s modified Eagle’s medium; ECM, extracellular matrix; EGCG, (→)-epigallocatechin-3-gallate; EMSA, electrophoretic mobility shift assay; FBS, fetal bovine serum; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; HSC, hepatic stellate cells; LDH, lactate dehydrogenase; NF-κB, nuclear factor-κB; RIPA, RIPA protection assay; α-SMA, α-smooth muscle actin; TjR-RII, type II TGF-β receptor; TGF-β, transforming growth factor-β; TUNEL, terminal transferase deoxyuridine end labelling.

* To whom correspondence should be addressed, at the Department of Pathology (e-mail achen@lsuhsc.edu).
was replaced every 12 h. The media with acetaldehyde was used for experiments. EGCG (purity > 95%), purchased from Sigma (St. Louis, MO, U.S.A.), was used in experiments at 95% (0.1 g). Acetaldehyde at 200 μM was widely used in previous HSC experiments [14,15]. Cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS). HSC at passages 4–8 were used for experiments. EGCG (purity > 95%), was used in experiments at the indicated concentrations. In some experiments, cells were serum-starved for 48 h prior to the addition of acetaldehyde (200 μM). Serum-depleted media (0.4% FBS) were used to minimize the formation of adducts between acetaldehyde and serum proteins. Acetaldehyde at 200 μM was widely used in previous HSC experiments [16]. The media with acetaldehyde was replaced every 12 h.

**Lactate dehydrogenase (LDH) release assays**

Pre-confluent passaged HSC (1–2 days post-plating) in 6-well plates were incubated in 1 ml of DMEM containing 10% FBS treated with EGCG at the indicated concentrations for 24 h. After centrifugation, LDH in the supernatant of the conditioned media was determined as medium LDH. Attached cells were lysed completely by 1 ml of 10% FBS/DMEM with Triton X-100 (0.1%). After centrifugation, LDH in the supernatant was analysed as cellular LDH. LDH in DMEM with 10% FBS was defined as contamination arising from FBS and subtracted from medium and cellular LDH values. LDH activities were determined with an LDH assay kit (Sigma). Results were shown as the percentage of total LDH, i.e. [medium LDH/(medium LDH + cellular LDH)] × 100%.

**Determination of cell growth**

Semi-confluent HSC (5.5 × 10^4/well) were serum-starved for 24 h in DMEM containing 0.4% FBS. Cells were maintained in DMEM with 0.4% FBS or subsequently stimulated with 10% FBS in the presence or absence of EGCG at the indicated concentrations for the indicated times. After washing, cell growth was determined by attached cell counts using a computer-equipped cell counter (Coulter Corporation, Miami, FL, U.S.A.).

**[3H]Thymidine-incorporation assays**

Passaged HSC (5.5 × 10^4/well) in 6-well plates were serum-starved for 24 h prior to treatments. Cells were then either maintained in serum-depleted media (0.4% FBS) or incubated in serum-rich media (10% FBS) with or without EGCG at the indicated concentrations for an additional 24 h and subsequently pulsed for 4 h with methyl-[3H]thymidine (1 μCi/ml; Amersham Bioscience, Arlington Heights, IL, U.S.A.). At the end of the incubation, cells were washed three times with cold PBS to remove unincorporated [3H]thymidine, followed by fixation with ice-cold methanol for 30 min at 4°C. Cells were lysed in 750 μl of 0.25 M NaCl/0.25% SDS. The reaction was stopped with 150 μl of 1 M HCl. The whole lysate was removed from each well and mixed with 4 ml of the scintillation fluid Soluscint O (National Diagnostics, Highland Park, NJ, U.S.A.) and counted in a liquid scintillation analyser. Results were expressed as c.p.m. from triplicate experiments.

**Bromodeoxyuridine (BrDU) staining**

Pre-confluent HSC in slideflasks were incubated in DMEM with 10% FBS with or without EGCG at the indicated concentrations for 24 h. Prior to harvesting cells (2 h), BrDU was added at a final concentration of 25 μg/ml. Cells were fixed and stained using a BrDU staining kit from Zymed, following the protocol provided by the manufacturer.

**Flow-cytometric analyses of the cell cycle and apoptosis**

Pre-confluent HSC incubated in DMEM with 10% FBS were treated with EGCG at 50 μM for the indicated times. Cells were harvested by brief trypsin/EDTA treatment and washed several times with cold PBS. HSC (≥ 1 × 10^6 cells/sample) were suspended in 2 ml of FACS buffer [1% FA buffer (Difco), 0.1% sodium azide and 1% FBS]. Cells were fixed with ethanol, and then labelled with propidium iodide (Sigma). Cells that were positively labelled with propidium iodide were detected with a Coulter® EPICS® XL-MCL flow cytometer and analysed using its System IT™ software.

**Detection of apoptotic HSC by terminal transferase deoxytytidyl uridine end labelling (TUNEL)**

Pre-confluent HSC cultured in DMEM with 10% FBS in slideflasks were treated with or without EGCG (50 μM) for the indicated times. Cells were washed three times with cold PBS before fixation. Apoptotic HSC were detected using the DeadEnd™ Colorimetric TUNEL System (Promega), following the protocol provided by the manufacturer.

**Western blotting analyses**

Whole-cell protein extracts were prepared from pre-confluent HSC treated with or without EGCG (50 μM). SDS/PAGE with 10% resolving gel was used to separate proteins (25 μg/lane). The separated proteins were detected by using primary antibodies and horseradish peroxidase-conjugated secondary antibodies (Santa Cruz Biotechnology, Santa Cruz, CA, U.S.A.). Protein bands were visualized by utilizing chemiluminescence reagent (Kirkegaard & Perry Laboratories, Gaithersburg, MD, U.S.A.).
Green tea polyphenol inhibits myofibroblast-like cell growth and activation

Figure 2 EGCG inhibits activated HSC growth

Passaged HSC (5.5 × 10^4/well) in 6-well plates were incubated in DMEM with 0.4% FBS for 24 h. Cells were then maintained in DMEM with 0.4% FBS, or stimulated with 10% FBS in the presence or absence of EGCG at the indicated concentrations for the indicated times. After washing, cell growth was determined by attached cell numbers. Values were expressed as means ± S.D. (n ≥ 6). Error bars, if not indicated, were contained within the data points. Values in parentheses are the percentage inhibition caused by EGCG compared with cells treated with 10% FBS.

Plasmids and transient transfection

The plasmid p3TP-Lux is a transforming growth factor-β (TGF-β)-inducible luciferase reporter, containing the plasminogen activator inhibitor-1 (PAI-1) gene promoter, kindly provided by Dr Joan Massague (Memorial Sloan-Kettering Cancer Center, NY, U.S.A.). The nuclear factor-κB (NF-κB) reporter plasmid pNF-κB-Luc was purchased from Clontech Laboratories (Palo Alto, CA, U.S.A.). The type II TGF-β receptor (Tβ-RII) reporter plasmid pTβ-RII (−219), containing 219 bp of the 5' promoter region of Tβ-RII gene, was generously provided by Dr Seong-Jin Kim (Laboratory of Chemoprevention, National Cancer Institute, National Institutes of Health, Bethesda, MD, U.S.A.) [18]. Transfection and luciferase assays were described previously [15]. Transfection efficiency was determined by co-transfection of a β-galactosidase reporter, pSV-β gal (0.5 μg/well; Promega).

RNA isolation and RNase protection assay (RPA)

Total RNA was isolated by the TRI Reagent (Sigma), following the protocol recommended by the manufacturer. To prepare RNA probes for Tβ-RII, pT7-Tβ-RII was linearized with EcoRI [19]. The 115 bp of 28 S rRNA probe was used as an internal control (Ambion, Austin, TX, U.S.A.). The antisense probes were synthesized and 32P-labelled by MAXiScript™ (Ambion). RPA was carried out using RPA II™ kits (Ambion) following the protocol provided by the manufacturer. The radioactivity in each band was measured using a PhosphorImager (Molecular Dynamics, Sunnyvale, CA, U.S.A.), as described previously [14,15].

Real-time PCR

DNase I-treated total RNA (1 μg) was used for synthesis of the first strand of cDNA. Reverse transcription conditions were as follows: 42 °C for 15 min, 95 °C for 5 min and 5 °C for 5 min (one cycle). Real-time PCR was carried out in 25 μl of reaction solution [2.5 μl of 10× buffer, 5 mM dNTPs, 10 mM MgCl₂, 200 nM primers and 0.75 units of platinum² Taq polymerase; all from Invitrogen] plus 1 μl of SYBR Green (1:2000; BioWhittaker, Richland, ME, U.S.A.). No genomic DNA contamination or pseudogenes were detected by PCR without the reverse transcription step in the total RNA used. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an internal control. The reactions started at 95 °C for 7 min, followed by 40 cycles of 95 °C for 20 s, 54 °C for 30 s and 72 °C for 30 s. Melting peaks of PCR products were determined by heat-denaturing them over a 35 °C temperature gradient at 0.2 °C/s from 60 to 95 °C [20]. The cycle numbers crossing an arbitrary threshold (Ct) were determined using Smart Cycler® software, version 1.2b (Cepheid, Sunnyvale, CA, U.S.A.). Fold change in target mRNA relative to GAPDH was calculated as suggested by Schmittgen et al. [20]:

Fold change = 2^(-ΔΔCt)

where

ΔΔCt = (Ct_target − Ct_GAPDH)time X − (Ct_target − Ct_GAPDH)time 0

Time X is any time point when the drug was given. Time 0 represents the experiment starting time (no drug added).

Primers used in the real-time PCR were: αI(I) collagen, forward, 5'- CCT CAA GGG CTC CAA GGA G-3'; reverse, 5'-TCA ATC ACT GTC TTG CCC CA-3'; α-SMA, forward, 5'-CCG ACC GAA TGC AGA AGG A-3'; reverse, 5'-ACA GAG
Table 1  
LDH release in cultured HSC treated with EGCG

The percentage of total LDH was calculated as \( \frac{\text{medium LDH}}{\text{medium LDH} + \text{cellular LDH}} \) \( \times 100\% \). Values are expressed as means \( \pm \) S.D. \( (n \geq 3) \).

<table>
<thead>
<tr>
<th>EGCG (( \mu M ))</th>
<th>0</th>
<th>20</th>
<th>50</th>
<th>100</th>
<th>1000</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total LDH (%)</td>
<td>8.7 ( \pm ) 0.8</td>
<td>8.5 ( \pm ) 0.3</td>
<td>7.4 ( \pm ) 0.7</td>
<td>8.8 ( \pm ) 0.7</td>
<td>38 ( \pm ) 0.6*</td>
</tr>
</tbody>
</table>

* \( P < 0.01 \), compared with cells with no EGCG treatment.

Electrophoretic mobility shift assay (EMSA)

EMSA was performed as described previously [14]. The integrity of nuclear extracts was tested by EMSA with a \( ^{32}\)P-labelled SP-1 consensus probe, resulting in distinct SP-1 shifts from all extracts (results not shown). The NF-\( \kappa \)B gel-shift probe was purchased from Santa Cruz Biotechnology.

Statistical analysis

Differences between means were evaluated using an unpaired two-sided Student’s \( t \) test. \( P < 0.05 \) was considered significant. Where appropriate, comparisons of multiple treatment conditions with controls were analysed by ANOVA with the Dunnett’s test for post hoc analysis.

RESULTS

EGCG inhibits cultured HSC growth

To begin to explore the effect of EGCG on activated HSC growth, serum-starved cells were maintained in DMEM with 0.4% FBS or stimulated with 10% FBS in the presence or absence of EGCG at the indicated concentrations for 8, 24 or 48 h. After washing, cell growth was determined by attached cell numbers. As shown in Figure 2, compared with cells maintained in DMEM with 0.4% FBS, 10% FBS significantly increased cell numbers, which was markedly reduced by EGCG. After 48 h incubation, compared with 10% FBS stimulation, EGCG at 20,
Green tea polyphenol inhibits myofibroblast-like cell growth and activation

Figure 4  EGCG results in re-distribution of activated HSC cell cycle

Pre-confluent activated HSC were treated with EGCG (50 μM) for the indicated times. After fixation and labelling with propidium iodide, cells positively labelled with propidium iodide were detected by flow cytometry. The percentage of cell numbers at each stage was from three independent experiments. The percentages shown are the difference in cell number caused by EGCG treatment for 24 h compared with cells with no EGCG treatment (control, ctr).

EGCG toxicity to HSC was carefully studied in cultured HSC by examining LDH release. EGCG, compared with the control, made no significant difference in LDH release at concentrations up to 100 μM (Table 1). Based on no detectable LDH release, and a rapid recovery of cell proliferation after withdrawal of EGCG (results not shown), it was concluded that EGCG up to 100 μM was not toxic to cultured HSC. EGCG at 50 μM was chosen for the following experiments. To elucidate mechanisms underlying EGCG inhibition of cultured HSC growth, we hypothesized that this antioxidant might reduce HSC proliferation and/or induce HSC apoptosis.

EGCG inhibits DNA synthesis in activated HSC

To evaluate the effect of EGCG on DNA synthesis and cell proliferation of cultured HSC, incorporation of methyl-[3H]thymidine and BrdU into chromosomal DNA was examined. Serum-starved HSC were either maintained in serum-depleted media (0.4% FBS), or incubated in serum-rich media (10% FBS), with or without EGCG at the indicated concentrations for 24 h and pulsed with methyl-[3H]thymidine. As shown in Figure 3(A), compared with 0.4% FBS, 10% FBS markedly stimulated incorporation of [3H]thymidine into chromosomal DNA of cultured HSC by 133%. EGCG at 20, 50 or 100 μM significantly reduced the [3H]thymidine incorporation by 14.3±1.4, 25.7±3.6 and 28.5±3.3%, respectively, suggesting that EGCG inhibited DNA synthesis and cell proliferation in a dose-dependent manner.

BrdU staining of cultured HSC confirmed that this antioxidant caused an apparent dose-dependent reduction in BrdU incorporation into chromosomal DNA (Figures 3B and 3C). Taken together, these results indicated that EGCG inhibited HSC proliferation in a dose-dependent manner.

EGCG inhibits activated HSC growth by inducing cell cycle arrest and apoptosis

Flow-cytometric assays were carried out to further evaluate the effect of EGCG on the cell cycle of activated HSC. As shown in Figure 4, compared with no EGCG controls, this antioxidant, in a time-dependent pattern, altered the percentage of cells in the G0/G1, S and G2/M phases by +3.6±0.6, −40.4±6.2 and −44.4±7.5%, respectively, after 24 h treatment. These results indicated that EGCG caused a cell cycle re-distribution of activated HSC by reducing cells staged at DNA synthesis and cell division, while increasing arresting cells. In addition, EGCG induced apoptosis of these activated HSC by 2-fold after 24 h treatment (Figure 4). TUNEL staining confirmed the effect of EGCG on induction of activated HSC apoptosis (Figure 5).

Western blotting analyses further demonstrated that EGCG apparently inhibited the expression of cell cycle-stimulating proteins, including cyclin D1 and D2, and cyclin E, in cultured HSC, while causing no notable change in cyclin D3 (Figure 6). In addition, EGCG induced a marked increase in cell cycle in-
Figure 5  EGCG induces time-dependent HSC apoptosis

Pre-confluent HSC cultured in DMEM with 10% FBS in slide flasks were treated with or without EGCG (50 µM) for the indicated times. After fixation, apoptotic HSC were detected by the DeadEnd™ Colorimetric TUNEL System. Representatives of activated HSC stained by TUNEL are presented (original magnification, × 100).

Figure 6  EGCG alters the expression of cell cycle proteins in activated HSC

Whole-cell protein extracts were prepared from pre-confluent HSC treated with or without EGCG (50 µM) for the indicated times. SDS/PAGE with 10% resolving gel was used to separate proteins (25 µg/lane). Cell cycle proteins were detected by using primary antibodies and horseradish peroxidase-conjugated secondary antibodies. Each result was representative of three independent Western blotting analyses. EGCG had no effect on cyclin D3 protein expression, which was used as an internal control for equal protein loading.

Inhibitory proteins, including p21\(^{WAF1/CIP1}\) and p27\(^{Kip1}\) (Figure 6). Taken together, these results revealed that EGCG inhibited HSC growth, at least, by inducing cell cycle arrest and apoptosis.

EGCG significantly inhibits NF-κB activity in activated HSC

Activation of NF-κB is closely associated with activation and survival of HSC [5,21,22]. Acetaldehyde, the major active metabolite of ethanol, directly induces HSC activation during alcohol-caused liver injury. Acetaldehyde induces oxidative stress and NF-κB activation in various cell types [23–25]. It was therefore of interest to elucidate the effect of the antioxidant EGCG on NF-κB activation induced by acetaldehyde in cultured HSC. As shown in EMSAs, compared with the control (Figure 7A, lane 1), acetaldehyde caused an apparent NF-κB-binding band (Figure 7A, lane 2). A 50-fold excess of the unlabelled probe markedly, if not completely, diminished the binding band in a competition assay (Figure 7A, lane 4), suggesting the specificity of the NF-κB binding to the probe. Anti-p50 antibodies (α-p50), but not normal rabbit IgG (results not shown), caused a significant supershift and abolished the NF-κB-binding band (Figure 7A, lane 5). Treatment of these cells with EGCG (50 µM) resulted in an apparent reduction in the density of the NF-κB-binding band (Figure 7A, lane 3), suggesting that EGCG reduced the NF-κB DNA-binding activity in cultured HSC.

To evaluate effects of EGCG on the NF-κB trans-activating ability, HSC were transfected with the NF-κB reporter plasmid pNF-κB-Luc. After recovery, cells were incubated in DMEM with 0.4 or 10% FBS, or 0.4% FBS plus acetaldehyde (200 µM), with or without EGCG (50 µM) for an additional 24 h (Figure 7B). Compared with 0.4% FBS, acetaldehyde or 10% FBS remarkably increased luciferase activities by 2.3- or 3.9-fold, respectively, in these cells. Pretreatment of cells with EGCG 3 h
Green tea polyphenol inhibits myofibroblast-like cell growth and activation

Figure 7  EGCG reduces NF-κB activity in activated HSC

(A) The EGCG effect on NF-κB DNA-binding activity analysed by EMSA, using a 32P-labelled NF-κB-binding probe. Nuclear proteins were from cultured HSC treated with (lane 3) or without 50 μM EGCG (lanes 1, 2, 4 and 5) in the presence (lanes 2-5) or absence (lane 1) of acetaldehyde (Ach; 200 μM). A 50-fold excess of the unlabelled probe was used for the competition assay (Compt.; lane 4). Anti-p50 antibodies (α-p50) were used for the supershift assay (lane 5). (B) The EGCG effect on the NF-κB trans-activating ability. After overnight recovery from transduction with pNF-κB-Luc, HSC were incubated in DMEM with 0.4% FBS with (black columns) or without (white columns) EGCG (50 μM) 3 h prior to the addition of 10% FBS, or acetaldehyde (200 μM), or nothing as a control, for an additional 24 h. Luciferase activities were expressed as relative units after β-galactosidase normalization (n = 6). *P < 0.05 versus corresponding cells without EGCG; **P < 0.05 versus cells with no treatment. Values above bars are the percentage inhibition caused by EGCG compared with corresponding cells without EGCG treatment (control, ctr).

prior to the addition of acetaldehyde (200 μM), or 10% FBS, significantly reduced luciferase activity by 58.7 ± 4.5 or 67.7 ± 4.9%, respectively, indicating that EGCG at 50 μM inhibited the NF-κB trans-acting activity in cultured HSC. Taken together, these results demonstrated that EGCG inhibited NF-κB activation in activated HSC. In addition, compared with the inhibitory efficiency in cells stimulated by acetaldehyde (−58.7 ± 4.5%) or 10% FBS (−67.7 ± 4.9%), the inhibitory effect of EGCG on reducing luciferase activity was significantly diminished in serum-starved HSC (−40 ± 2.5%). These results suggested that EGCG, with respect to inhibition of NF-κB activity, allowed a distinction to be made between cells with different activation status.

EGCG suppresses the expression of α1(I) collagen, fibronectin and α-SMA induced by acetaldehyde

We and others have previously demonstrated that acetaldehyde induced the expression of ECM, including α1(I) collagen, fibronectin and α-SMA in HSC [15,16,26]. To assess the effect of EGCG on the expression of genes induced by acetaldehyde, passaged HSC were serum-starved for 48 h prior to induction with or without acetaldehyde (200 μM) in the presence or absence of EGCG at the indicated concentrations for an additional 24 h. Real-time PCR revealed that, compared with the untreated serum-starved control, acetaldehyde increased the mRNA abundance of α1(I) collagen, fibronectin, and α-SMA in these cells (Figure 8). EGCG treatment resulted in a marked dose-dependent reduction in the mRNA abundance increased by acetaldehyde (Figure 8), suggesting that EGCG inhibited the expression of these genes induced by acetaldehyde. Interestingly, the EGCG effect on inhibition of the expression of these genes was significantly diminished in serum-starved HSC without acetaldehyde stimulation (Figure 8). For example, compared with levels of mRNA in cells treated with acetaldehyde only, EGCG (50 μM) caused a significant reduction in the mRNA levels of α1(I) collagen, fibronectin and α-SMA by 49, 95 and 53%, respectively. In great contrast, compared with mRNA levels in cells without acetaldehyde treatment, EGCG at 50 μM only resulted in a slight reduction in the mRNA levels of α1(I) collagen, fibronectin and α-SMA by 15, 10 and 21%, respectively. This observation suggested that EGCG, regarding the inhibition of gene expression, might have an ability to distinguish cells based on their activation status. It bears mention that the expression of these...
A. Chen and others

Figure 8 EGCG suppresses the expression of genes induced by acetaldehyde

Passaged HSC were serum-starved for 48 h prior to the treatment with or without acetaldehyde (200 µM) in the presence or absence of EGCG at the indicated concentrations for an additional 24 h. The mRNA abundance of α1(I) collagen, fibronectin and α-SMA in the cells was determined by real-time PCR. Acetaldehyde or EGCG had no effect on GAPDH mRNA. The mRNA fold change was calculated by using GAPDH as an internal control (see the Materials and methods section for details). Values were expressed as means ± S.D. from three independent experiments. *P < 0.05 versus cells treated with acetaldehyde only, without EGCG; †P < 0.05 versus cells with no treatment. Values shown above the bars on the left-hand panel are the percentage inhibition caused by EGCG compared with cells grown in DMEM with 0.4% FBS, without EGCG; those on the right-hand panel are the percentage inhibition caused by EGCG compared with cells stimulated with acetaldehyde, without EGCG.

genes was at a relatively low level in these serum-starved cells. Without acetaldehyde induction, the EGCG effect on gene expression was hardly detectable by Northern blots (results not shown).

**EGCG inhibits TGF-β signalling and reduces Tβ-RII mRNA induced by acetaldehyde in HSC**

Our recent studies showed that acetaldehyde activated TGF-β signal transduction and induced the expression of the Tβ-RII gene in cultured HSC [26a], which made a significant contribution to α1(I) collagen gene expression in activated HSC. To elucidate mechanisms by which EGCG inhibited α1(I) collagen gene expression in cultured HSC, it was hypothesized that EGCG suppressed TGF-β signal transduction induced by acetaldehyde. To study this hypothesis, passaged HSC were transfected with p3TP-Lux, a TGF-β-inducible luciferase reporter plasmid. Cells were then pre-treated with EGCG at the indicated concentrations 3 h prior to the addition of acetaldehyde (200 µM). Compared with the control, which received no EGCG pre-treatment, EGCG caused a dose-dependent reduction in luciferase activity in these cells (Figure 9A), suggesting that EGCG inhibited acetaldehyde-activated TGF-β signal transduction. RPA further demonstrated that EGCG, in a dose-dependent fashion, apparently reduced the level of Tβ-RII mRNA (Figure 9B), indicating that EGCG suppressed Tβ-RII gene expression induced by acetaldehyde.

**DISCUSSION**

To explore mechanisms of re-distribution of activated HSC cell cycle by EGCG, in the present studies we observed that this antioxidant reduced the expression of cyclins D1, D2 and E, as well as induced the expression of p21WAF1/Cip1 and p27Kip1. Similar EGCG effects on the expression of cell cycle proteins were observed in human epidermoid carcinoma cells (A431) [27]. Previous studies have indicated that the expression of particular cyclin Ds and activities of certain cyclin-dependent kinases (Cdk), as well as Cdk-inhibitory proteins (CKI), probably decided the fate of cells [28]. It was suggested that D-type cyclins might play critical roles in cell cycle progression, especially at early G1/G0 phase [29,30]. Over-expression of cyclin D1 in fibroblasts caused a short G1 phase and dysregulation of gene expression, as well as enhanced tumorigenesis [31]. In contrast, microinjection of anti-cyclin D1 antibodies or antisense cyclin D1 cDNA prevented cells from entering the S phase [32]. These results collectively demonstrated that cyclin D1 was a critical target of proliferative signals in G1. Another recent study suggested that cyclins D1, D2


Figure 9  EGCG inhibits TGF-β signal transduction and reduces the Tβ-RII mRNA abundance increased by acetaldehyde in cultured HSC

Prior to (3 h) stimulation with 200 μM acetaldehyde, EGCG at the indicated concentrations was added to HSC transfected with (A) p3TP-Lux, a TGF-β-inducible luciferase reporter plasmid (see the Materials and methods section for details). (A) Luciferase assays of HSC transfected with p3TP-Lux. Luciferase activities were analysed and expressed as relative units after β-galactosidase normalization (n ≥ 6). *P < 0.05 versus cells treated with acetaldehyde, without EGCG. (B) RPA of endogenous Tβ-RII mRNA of cultured HSC. 28 S rRNA was used as an internal control. Ctr, control.

and E played a key role in transition of HSC cell cycle from the G1 to the S phase [33].

Acute liver injury in vivo is first accompanied by activation and proliferation of HSC with no sign of apoptosis [34]. In the recovery phase, apoptotic HSC are detectable in parallel to a reduction in the total number of activated HSC present in the liver tissue [34]. Induction of apoptosis was recently proposed as a strategy to terminate proliferation of activated HSC for prevention of hepatic fibrogenesis [3,4]. The present study suggests that the reduction of cell numbers by EGCG might reflect a combined result of both inhibition of cell proliferation and induction of cell apoptosis, which could explain the apparent difference in the percentage between cell numbers (Figure 2) and [3H]thymidine/BrdU incorporation (Figure 3). Further experiments in this report confirmed that EGCG not only inhibited activated HSC proliferation, but also induced apoptosis of these cells in vitro. Additional studies are necessary to elucidate effects of this antioxidant on regulating pro-apoptotic and anti-apoptotic proteins at levels of ligand bioavailability, receptor expression and signal generation, transduction and execution in activated HSC.

NF-κB has been described as a primary regulator and mediator of oxidative stress. It has been implicated in cell proliferation, cell cycle regulation and apoptosis [35]. Although the causal relationship remains unknown, previous studies demonstrated that activation and survival of HSC was closely associated with activation of NF-κB [5,21,22]. It was suggested that inhibition of NF-κB activation was a potential strategy for prevention and/or therapy of cirrhosis [21]. Previous studies indicated that oxidative stress, through inducing NF-κB activity, played an essential role in HSC activation [5]. Our present results demonstrated that EGCG significantly inhibited NF-κB activity induced by acetaldehyde in cultured HSC. In addition, as shown in Figure 7(B), EGCG allowed a distinction in the inhibition of NF-κB activity between serum-starved HSC with or without a stimulation to be made. Many previous studies believed that serum-starvation of activated HSC for 48 h rendered them quiescent [36,37]. The EGCG effect on differential inhibition of NF-κB activity has also been reported previously. For example, EGCG resulted in a dose-based differential inhibition of tumour necrosis factor-α- and lipopolysaccharide-mediated activation of NF-κB in cancer cells, but not in normal cells [38,39]. Similarly, in this communication we observed that EGCG differentially inhibited the expression of ECM genes between serum-starved HSC, with or without acetaldehyde stimulation (Figure 9). The underlying mechanisms of the differential inhibition remain poorly understood.

Accumulating evidence has indicated a close link between alcohol and TGF-β in the process of hepatic fibrogenesis during liver injury [40,41]. Our recent studies observed that acetaldehyde activated TGF-β signal transduction and induced the expression of Tβ-RII, which played a marked role in acetaldehyde-induced increased expression of z1(I) collagen gene in HSC [26a]. The present results revealed that EGCG inhibited TGF-β signalling and reduced the abundance of Tβ-RII mRNA induced by acetaldehyde in cultured HSC, which, at least partially, explained the observation that EGCG inhibited the expression of the z1(I) collagen gene in HSC. Further experiments are necessary to elucidate the involved mediators and signal transduction pathways.

In summary, in this communication we have demonstrated for the first time that EGCG, a major component of green tea extracts, inhibits activated HSC growth, at least, by inducing cell cycle arrest and apoptosis. This antioxidant reduced the expression of cyclins D1, D2, and E, while inducing the expression of p27[1(Kip1)] and p16[1(INK4a)]. In addition, EGCG suppressed acetaldehyde-induced HSC activation, as demonstrated by inhibiting NF-κB activity, blocking TGF-β signal transduction and reducing the expression of α-SMA and ECM genes. Taken together, our results suggest that EGCG is a novel and effective inhibitor for activated HSC growth and activation in vitro. It should be emphasized that the results in this report were generated from cultured HSC, and that they might not necessarily and comprehensively reflect the situation in quiescent HSC in vivo. Additional experiments are necessary to determine effects of EGCG on cell growth and activation of quiescent HSC stimulated by alcohol/acetaldehyde in vitro and in vivo. It remains poorly
understood how EGCG could make a differential inhibition of NF-κB activation, or gene expression among cultured HSC with different activation status. Additional experiments, beyond the scope of this report, are necessary to investigate the underlying mechanism. Answers to this puzzle might provide a novel insight into the long history of green tea consumption without adverse health effects, while potentially preventing oxidative stress-related diseases. The characteristics of EGCG, including antioxidant potential, reduction of activated HSC growth, inhibition of NF-κB activation, induction of apoptosis and no adverse health effects, make it a potential anti-fibrotic candidate for treatment and prevention of hepatic fibrogenesis.

The work was supported by a National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases grant to A.C., and by seedling funds from the Department of Pathology, Louisiana State University Health Sciences Center in Shreveport, Shreveport, LA, U.S.A. Thanks to Dr Kevin J. McCarthy and Dr Stephen B. Pruett for comments and careful reading of the manuscript.

REFERENCES